• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    6/24/24 1:35:23 PM ET
    $AMGN
    $BNTX
    $HIMS
    $INSM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMGN alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    NVAX CALL TRADE BEARISH 06/28/24 $15.00 $129.4K 1.0K 2.4K
    INSM PUT TRADE BULLISH 01/17/25 $70.00 $810.0K 0 2.0K
    HIMS CALL TRADE BEARISH 06/28/24 $24.00 $65.2K 1.2K 1.4K
    MDT CALL TRADE BULLISH 06/28/24 $80.00 $79.7K 255 421
    VKTX CALL TRADE BULLISH 01/17/25 $25.00 $77.4K 984 61
    RXRX CALL SWEEP BULLISH 12/20/24 $10.00 $41.0K 205 19
    AMGN CALL TRADE BULLISH 12/20/24 $350.00 $36.9K 18 10
    SOLV PUT SWEEP BEARISH 07/19/24 $55.00 $25.4K 181 2
    LLY CALL TRADE BEARISH 12/18/26 $1200.00 $31.9K 21 2
    BNTX PUT TRADE BULLISH 07/19/24 $120.00 $77.1K 0 0

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For NVAX (NASDAQ:NVAX), we notice a call option trade that happens to be bearish, expiring in 4 day(s) on June 28, 2024. This event was a transfer of 5627 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $129.4K, with a price of $23.0 per contract. There were 1004 open contracts at this strike prior to today, and today 2432 contract(s) were bought and sold.

    • Regarding INSM (NASDAQ:INSM), we observe a put option trade with bullish sentiment. It expires in 207 day(s) on January 17, 2025. Parties traded 1000 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $810.0K, with a price of $810.0 per contract. There were 0 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold.

    • Regarding HIMS (NYSE:HIMS), we observe a call option trade with bearish sentiment. It expires in 4 day(s) on June 28, 2024. Parties traded 2835 contract(s) at a $24.00 strike. The total cost received by the writing party (or parties) was $65.2K, with a price of $23.0 per contract. There were 1283 open contracts at this strike prior to today, and today 1454 contract(s) were bought and sold.

    • Regarding MDT (NYSE:MDT), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on June 28, 2024. Parties traded 582 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $79.7K, with a price of $137.0 per contract. There were 255 open contracts at this strike prior to today, and today 421 contract(s) were bought and sold.

    • Regarding VKTX (NASDAQ:VKTX), we observe a call option trade with bullish sentiment. It expires in 207 day(s) on January 17, 2025. Parties traded 26 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $77.4K, with a price of $2980.0 per contract. There were 984 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold.

    • For RXRX (NASDAQ:RXRX), we notice a call option sweep that happens to be bullish, expiring in 179 day(s) on December 20, 2024. This event was a transfer of 200 contract(s) at a $10.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $41.0K, with a price of $205.0 per contract. There were 205 open contracts at this strike prior to today, and today 19 contract(s) were bought and sold.

    • For AMGN (NASDAQ:AMGN), we notice a call option trade that happens to be bullish, expiring in 179 day(s) on December 20, 2024. This event was a transfer of 30 contract(s) at a $350.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $1230.0 per contract. There were 18 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold.

    • For SOLV (NYSE:SOLV), we notice a put option sweep that happens to be bearish, expiring in 25 day(s) on July 19, 2024. This event was a transfer of 67 contract(s) at a $55.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.4K, with a price of $380.0 per contract. There were 181 open contracts at this strike prior to today, and today 2 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a call option trade that happens to be bearish, expiring in 907 day(s) on December 18, 2026. This event was a transfer of 3 contract(s) at a $1200.00 strike. The total cost received by the writing party (or parties) was $31.9K, with a price of $10635.0 per contract. There were 21 open contracts at this strike prior to today, and today 2 contract(s) were bought and sold.

    • For BNTX (NASDAQ:BNTX), we notice a put option trade that happens to be bullish, expiring in 25 day(s) on July 19, 2024. This event was a transfer of 23 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $77.1K, with a price of $3355.0 per contract. There were 0 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $BNTX
    $HIMS
    $INSM

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Amgen Inc.
    $AMGN
    2/20/2026$185.00Equal Weight
    Barclays
    Medtronic plc.
    $MDT
    2/13/2026$116.00Overweight
    Barclays
    Medtronic plc.
    $MDT
    2/9/2026$121.00Hold → Buy
    Needham
    Medtronic plc.
    $MDT
    2/3/2026$117.00Buy
    Citigroup
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    Medtronic plc.
    $MDT
    1/30/2026$114.00Overweight
    Wells Fargo
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    More analyst ratings

    $AMGN
    $BNTX
    $HIMS
    $INSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMGN
    $BNTX
    $HIMS
    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Amgen with a new price target

    Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00

    2/20/26 8:23:35 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on Medtronic with a new price target

    Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00

    2/13/26 8:31:53 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMGN
    $BNTX
    $HIMS
    $INSM
    SEC Filings

    View All

    SEC Form 8-K filed by Amgen Inc.

    8-K - AMGEN INC (0000318154) (Filer)

    2/19/26 4:27:56 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Recursion Pharmaceuticals Inc.

    144 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    2/19/26 10:27:19 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Insmed Incorporated

    10-K - INSMED Inc (0001104506) (Filer)

    2/19/26 7:01:18 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMGN
    $BNTX
    $HIMS
    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

    Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years  Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's diseaseINDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE:LLY) showed Omvoh (mirikizuma

    2/19/26 12:15:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $BNTX
    $HIMS
    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AMGN
    $BNTX
    $HIMS
    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Finance & CAO Busch Matthew C. sold $375,790 worth of shares (1,000 units at $375.79), decreasing direct ownership by 23% to 3,423 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    2/20/26 7:43:21 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Gibson Christopher converted options into 40,000 shares, sold $138,400 worth of shares (40,000 units at $3.46) and covered exercise/tax liability with 27,265 shares, decreasing direct ownership by 3% to 906,556 units (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    2/19/26 7:30:51 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Hallett David covered exercise/tax liability with 11,908 shares, decreasing direct ownership by 1% to 1,097,151 units (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    2/19/26 7:30:57 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $BNTX
    $HIMS
    $INSM
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $BNTX
    $HIMS
    $INSM
    Financials

    Live finance-specific insights

    View All

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

    —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million——Total Company Revenues of $606.4 Million for Full-Year 2025——BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025——ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance——Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track——FDA grants Orphan Drug Designation to Trepro

    2/19/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

    Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm

    2/18/26 8:30:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $BNTX
    $HIMS
    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    11/14/24 1:22:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioNTech SE

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    11/13/24 5:00:57 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care